Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Combination therapy of zonisamide and bupropion for weight reduction in obese women: a preliminary, randomized, open-label study.

Gadde KM, Yonish GM, Foust MS, Wagner HR.

J Clin Psychiatry. 2007 Aug;68(8):1226-9.

PMID:
17854247
2.

Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial.

Gadde KM, Yonish GM, Wagner HR 2nd, Foust MS, Allison DB.

Int J Obes (Lond). 2006 Jul;30(7):1138-42. Epub 2006 Jan 17.

PMID:
16418753
3.

Zonisamide for weight loss in obese adults: a randomized controlled trial.

Gadde KM, Franciscy DM, Wagner HR 2nd, Krishnan KR.

JAMA. 2003 Apr 9;289(14):1820-5.

PMID:
12684361
4.

Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women.

Gadde KM, Parker CB, Maner LG, Wagner HR 2nd, Logue EJ, Drezner MK, Krishnan KR.

Obes Res. 2001 Sep;9(9):544-51.

5.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
6.

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.

Jain AK, Kaplan RA, Gadde KM, Wadden TA, Allison DB, Brewer ER, Leadbetter RA, Richard N, Haight B, Jamerson BD, Buaron KS, Metz A.

Obes Res. 2002 Oct;10(10):1049-56.

7.

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, Kim DD, Dunayevich E; COR-I Study Group.

Lancet. 2010 Aug 21;376(9741):595-605. doi: 10.1016/S0140-6736(10)60888-4. Epub 2010 Jul 29. Erratum in: Lancet. 2010 Aug 21;376(9741):594. Lancet. 2010 Oct 23;376(9750):1392.

PMID:
20673995
8.

Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial.

McElroy SL, Kotwal R, Guerdjikova AI, Welge JA, Nelson EB, Lake KA, D'Alessio DA, Keck PE, Hudson JI.

J Clin Psychiatry. 2006 Dec;67(12):1897-906. Erratum in: J Clin Psychiatry. 2007 Jan;68(1):172.

PMID:
17194267
9.

An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.

Dastjerdi MS, Kazemi F, Najafian A, Mohammady M, Aminorroaya A, Amini M.

Int J Obes (Lond). 2007 Apr;31(4):713-7. Epub 2006 Sep 12.

PMID:
16969361
10.
11.

Zonisamide in the treatment of binge-eating disorder: an open-label, prospective trial.

McElroy SL, Kotwal R, Hudson JI, Nelson EB, Keck PE.

J Clin Psychiatry. 2004 Jan;65(1):50-6.

PMID:
14744168
12.

A randomized controlled trial of two weight-reducing short-term group treatment programs for obesity with an 18-month follow-up.

Stahre L, Tärnell B, Håkanson CE, Hällström T.

Int J Behav Med. 2007;14(1):48-55.

PMID:
17511533
13.
14.

Triple-combination pharmacotherapy for medically ill smokers: a randomized trial.

Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, Carson JL.

Ann Intern Med. 2009 Apr 7;150(7):447-54.

PMID:
19349630
15.

Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients.

Kaya A, Aydin N, Topsever P, Filiz M, Oztürk A, Dağar A, Kilinç E, Ekmekcioglu C.

Biomed Pharmacother. 2004 Dec;58(10):582-7.

PMID:
15589067
16.

Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.

Shinnar S, Pellock JM, Conry JA.

Eur J Paediatr Neurol. 2009 Jan;13(1):3-9. doi: 10.1016/j.ejpn.2008.01.004. Epub 2008 Mar 14.

PMID:
18343174
17.

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.

Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.

Diabetes Care. 2007 Jan;30(1):27-32.

PMID:
17192328
18.

Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.

Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D.

Int J Obes (Lond). 2008 Apr;32(4):692-9. Epub 2007 Dec 11.

PMID:
18071341
19.

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

Anderson JW, Greenway FL, Fujioka K, Gadde KM, McKenney J, O'Neil PM.

Obes Res. 2002 Jul;10(7):633-41.

20.

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Erratum in: Clin Ther. 2008 Oct;30(10):1937.

PMID:
18803987

Supplemental Content

Support Center